Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
Executive Highlights The POD1UM-304 phase 3 trial marks a significant milestone in the management of…
This article reviews the phase 3 POD1UM-304 trial demonstrating that adding retifanlimab to platinum-based chemotherapy improves overall survival in first-line metastatic NSCLC, highlighting its potential as a new standard of care.
The POD1UM-304 study demonstrated that adding the PD-1 inhibitor retifanlimab to platinum-based chemotherapy significantly improves overall survival in patients with first-line metastatic non-small-cell lung cancer, offering a new therapeut
Retifanlimab combined with carboplatin-paclitaxel significantly prolongs progression-free survival in advanced squamous cell anal cancer, offering a promising new first-line standard of care.